Previous 10 | Next 10 |
Montrouge, France, February 24, 2020 DBV Technologies to Present Detailed Safety and Efficacy Data of Viaskin Peanut at AAAAI 2020 DBV Technologies (Euronext: DBV – ISIN: FR0010417345 – Nasdaq Stock Market: DBVT), a clinical-stage biopharmaceutical company, today announced ...
Montrouge, France, February 21, 2020 DBV Technologies Announces FDA Advisory Committee Meeting to Review Viaskin Peanut for the Treatment of Peanut Allergy in Children DBV Technologies (Euronext: DBV - ISIN: FR0010417345 - Nasdaq Stock Market: DBVT), a clinical-stage biopharmaceutical...
Montrouge, France, February 10, 2020 DBV Technologies to Present at the SVB Leerink 9th Annual Global Healthcare Conference DBV Technologies (Euronext: DBV – ISIN: FR0010417345 – Nasdaq Stock Market: DBVT), a clinical-stage biopharmaceutical company, today announced that...
Aimmune Therapeutics Inc (NASDAQ: AIMT) -- a California-based biotechnology company -- recently made history. The company's drug Palforzia became the first treatment for peanut allergies to be approved by the U.S. Food and Drug Administration (FDA). Naturally, investors received the news w...
Monthly information regarding the total number of voting rights and total number of shares of the Company as of January 31, 2020 and February 4, 2020 (Article 223-16 of the General Regulations of the Autorité des Marchés Financiers ) Market : NYSE Euronext Pari...
Montrouge, France, February 6, 2020 DBV Technologies Announces Appointment of Pascal Wotling as Chief Technical Operations Officer DBV Technologies (Euronext: DBV - ISIN: FR0010417345 - Nasdaq Stock Market: DBVT), a clinical-stage biopharmaceutical company, today announced the appointmen...
Aimmune Therapeutics (NASDAQ: AIMT) won approval from the U.S. Food and Drug Administration for its first drug -- and there are two more important firsts. Aimmune's Palforzia is the first approved drug to treat peanut allergies, and the first approved treatment for any kind of food allergy,...
Aimmune Gets a Boost as FDA Green Signals Allergy Medication Aimmune Therapeutics ( AIMT ) received FDA nod for its peanut allergy medication Palforzia. This orally administered medication aims to mitigate allergic reactions caused by exposure to peanuts. While it is not designed to be an ...
Gainers: Datasea (NASDAQ: DTSS ) +81% . More news on: Datasea Inc., Sintx Technologies, Inc., ReTo Eco-Solutions, Inc., Stocks on the move, , Read more ...
Sundial Growers (NASDAQ: SNDL ) -26% on CEO exit . More news on: Sundial Growers Inc., Briggs & Stratton Corporation, Intelsat S.A., , Stocks on the move, Read more ...
News, Short Squeeze, Breakout and More Instantly...
DBV Technologies S.A. Company Name:
DBVT Stock Symbol:
NASDAQ Market:
DBV Technologies S.A. Website:
Information regarding the total number of voting rights and total number of shares of the Company as of July 31, 2024 (Article 223-16 of the General Regulations of the Autorité des Marchés Financiers ) Market : NYSE Euronext Paris ISIN Code: FR 0010417345 ...
Châtillon, France, July 30, 2024 DBV Technologies Announces Filing of 2024 Half-Year Report ― Conditions for Accessing or Consulting the Report DBV Technologies (Euronext: DBV – ISIN: FR0010417345 – Nasdaq Stock Market: DBVT), a clinical-stage biopharmaceutic...
Châtillon, France, July 30, 2024 DBV Technologies Provides Updates on the Viaskin Peanut Program in Children and Toddlers and Reports Second Quarter and Half-Year 2024 Financial Results VITESSE enrollment in peanut allergic 4-7-year-olds is on-track and recruitment is expecte...